Eiger's Lonafarnib Loses EU Fast-Track Review Status
Potential Progeria Treatment Has Reverted To Standard Review
Executive Summary
Eiger attributes the change in status of the EU marketing authorization application for lonafarnib to the need for an inspection and the ongoing coronavirus pandemic.
You may also be interested in...
Orphazyme Wants More Time To Deal With Late-Stage Issues For Arimoclomol In EU
Following Orphazyme’s disappointment in the US regarding its investigational drug for an ultrarare disease, the company has said it will need more time to address outstanding issues raised by EU reviewers about the same medicine.
EU Fast-Track Loss For GSK's Dostarlimab
GSK’s potential endometrial cancer treatment dostarlimab is one of two products to revert to standard review timelines in recent weeks.
Review Of BMS's CAR-T Therapy Liso-Cel Gets Under Way At EMA
Bristol Myers Squibb's lisocabtagene maraleucel, UCB's bimekizumab and Rhythm Pharmaceuticals' setmelanotide are among the six latest additions to the list of products under review at the European Medicines Agency.